NL-OMON39447已完成2 期
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer*s Disease or Mild Alzheimer's Disease - Eli Lilly I40 MC BACC
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Eli Lilly
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Inclusion Criteria:
- •Patients may be included in the study only if they meet all of the following criteria:
- •[1] Present with MCI due to AD or mild AD based on the disease diagnostic criteria (Section 8.1.1).
- •[2] Are men or postmenopausal women, at least 55 years of age. Postmenopausal women are defined as women who have had a hysterectomy and/or bilateral oophorectomy; or who have been amenorrheic for at least 2 years.
- •[3] Have a reliable caregiver/study informant who provides a separate written informed consent to participate and who is in frequent contact with the patient (defined as at least 10 hours per week). The caregiver/study informant must be able to communicate with site personnel and in the investigator*s opinion must have adequate literacy to complete the protocol-specified questionnaires. If a caregiver/study informant cannot continue, 1 replacement is allowed.
- •[4] Have adequate vision (have not met exclusion criteria 12) and hearing for neuropsychological testing in the opinion of the investigator
- •[5] Have adequate premorbid literacy in the investigator*s opinion to complete the required psychometric tests
- •[6] Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site
排除标准
- •Exclusion Criteria:
- •Subjects will be excluded from the study if they meet any of the following criteria:
- •[7] Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or nonapproved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- •[8] Diagnosis or history of other possible etiology of dementia, including but not limited to other neurodegenerative disorders
- •[9] Has received acetylcholinesterase inhibitors (ACHEIs), memantine and/or other AD therapy for <2 months or has <4 weeks of stable therapy on these treatments by Visit 1, or, in the opinion of the investigator, the patient will not likely remain on stable treatment regimen for 6 months. Note: If a patient has recently stopped ACHEIs and/or memantine, he or she must have discontinued treatment at least 4 weeks before Visit 1. Patients not treated with anti-Alzheimer drugs are eligible for study enrollment.
- •[10] Has frontotemporal dementia, Lewy body disease, vascular dementia, Huntington*s Disease or concomitant Parkinson*s disease, progressive supranuclear palsy (PSNP) or other movement disorder, or active autoimmune or neuroimmunologic disorders causing dementia or cognitive impairment
- •[11] Has B12 <200 pg/ml (<148 pmol/L), or folate <7.5 nmol/L (<3.3 ng/ml) indicating vitamin deficiency
- •[12] Patients with significant retinal impairment:
- •morphological retinal impairment (based on the 3-field visual photography and, OCT).
- •significant (moderate or severe) dry or any untreated wet age-related macular degeneration.
- •other significant retinal diseases (such as diabetic retinopathy),
- •retinal vascular occlusions that are visually significant
- •clinically significant epiretinal membrane (or macular pucker) or a clinically significant macular hole
- •functional impairment, such as:
- •corrected visual acuity less than 20/40 in each eye, as measured on the Snellen, ETDRS or equivalent chart
- •VFQ-25, with a baseline global score of less than 70
- •increased intraocular pressure (non-treated glaucoma)
- •Opthalmological diagnostic and exclusion criteria will be defined in Manual of Operations provided to the sites.
- •[13] Has a history within the past 5 years of a serious infectious disease affecting the brain, including meningitis, or encephalitis
- •[14] Severe or recurrent head injury that is clinically relevant to the disease under study, (that is, with permanent neurological/cognitive sequelae)
- •[15] Onset of dementia following heart surgery or cardiac arrest
- •[16] Abnormal thyroid function: Thyroid Stimulating Hormone (TSH) values are outside of the normal range 0.3-5.6 mIU/L. (NOTE: patients with stable treatment of hypothyroidism and with normal value of TSH will be allowed to enter the study).
- •[17] Diagnosis or history of cerebrovascular disease (for example, stroke, transient ischemic attack), severe carotid stenosis, cerebral hemorrhage, intracranial tumor, subarachnoid hemorrhage, or subdural hematoma that could contribute to the subject's current cognitive or functional status, impair ability to fully participate in the trial or that may impact health status.
- •[18] Has had a PET scan within 6 months of the scheduled imaging at Visit 2;[19] Are being monitored fo
研究者
相似试验
进行中（未招募）
不适用
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer'sDisease or Mild Alzheimer's DiseaseEUCTR2011-005217-37-ITELI LILLY AND COMPANY260
进行中（未招募）
不适用
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's DiseaseMild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's DiseaseMedDRA version: 14.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2011-005217-37-NLEli Lilly and Company260
进行中（未招募）
不适用
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's DiseaseMild Cognitive Impairment Due to Alzheimer?s Disease or Mild Alzheimer's DiseaseMedDRA version: 15.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-005217-37-ESEli Lilly and Company260
招募中
1 期
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's DiseaseMild Cognitive Impairment due to Alzheimer's Disease or mild Alzheimer DiseaseJPRN-jRCT2080221890Eli Lilly Japan K.K.
已完成
不适用
Pharmacokinetics and safety of DA-6034KCT0000793Dong-A Pharm67